Investigation the effect of aqueous extract of salvia mirzayanii in treatment of diabetes

Clinical trial of the effect of aqueous extract of Salvia mirzayani in control of blood sugar of type 2 diabetic patients in comparison with control group

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015122725712N1

Enrollment

Registered

2017-04-27

Start date

2016-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes disease based on WHO guide line. Non insulin dependent diabetes

Interventions

Intervention 1: Interventional group: Every day one hour after lunch, patients of interventional group receive 1 capsule containing 450 mg of aqueous extract of Salvia mirzayanii for 3 months. Interve

Placebo

Treatment - Drugs

Interventional group: Every day one hour after lunch, patients of interventional group receive 1 capsule containing 450 mg of aqueous extract of Salvia mirzayanii for 3 months.

Control group: Every day one hour after lunch, patients of this group receive 1 placebo capsule containing 450 mg of caramelized flour and 5% of aqueous extract of Salvia mirzayanii for 3 months.

Eligibility

Sex/Gender

All

Age

19 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria include patients with the age range between 19 and 65 years; patients having diabetes mellitus based on the guideline of the WHO 1999; Patients with BMI were >19 Kg/m2 and 30, who have not any other diseases; Patients without insulin therapy and any other complications; Patients with HbA1C > 7% and blood sugar> 7 mmol/ l Exclusion criteria’s include pregnant women, or women wanted to become Pregnant; Patients with active infections or hepatitis C, B, HIV or TB (or in TB therapy); Cancer patients (except patients with skin cancer); patients using steroids such as prednisone for the treatment of a chronic disease; patients smoking cigarettes and drinking alcohol; patients with blood pressure higher than 160/90; usage of contraceptive pill by women; Moreover, patients with malabsorption; chronic diarrhea; liver and kidney diseases; ischemia heart failure; anemia; heart attack; peripheral vascular disease and diabetic nephropathy are excluded from the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HbA1C. Timepoint: in the beginnig of study and after 3 months of intervention. Method of measurement: by kit.;Levels of liver enzymes. Timepoint: beginning of the study and after 3 months of intervention. Method of measurement: by kit.;Lipid profile. Timepoint: beginning of the study and after 3 months of intervention. Method of measurement: by kit.;Fasting Blood Sugar(FBS). Timepoint: in the beginnig of the study and after 3 months of intervention. Method of measurement: by kit.	—

Measure

Time frame

HbA1C. Timepoint: in the beginnig of study and after 3 months of intervention. Method of measurement: by kit.;Levels of liver enzymes. Timepoint: beginning of the study and after 3 months of intervention. Method of measurement: by kit.;Lipid profile. Timepoint: beginning of the study and after 3 months of intervention. Method of measurement: by kit.;Fasting Blood Sugar(FBS). Timepoint: in the beginnig of the study and after 3 months of intervention. Method of measurement: by kit.

—

Secondary

Measure	Time frame
BMI. Timepoint: in the beginnig of the study and after 3 months of intervention. Method of measurement: Balance.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Soheila Moein

Hormozgan University of Medical Sciences

soheila_9@yahoo.com; smoein@razi.tums.ac.ir+98 76 3366 8476

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026